POSTER PROGRAM

Tuesday 20 February 2018

16:15 – 17:45	**POSTER DISCUSSION 1: BASIC VACCINE CONCEPTS AND CORRELATES OF PROTECTIVE IMMUNITY**
Roshanara	Facilitators: David Lewinsohn, Oregon Health & Science University (USA) | Vinay Kumar Nandicoori, National Institute of Immunology (India)
PD-01	**Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) exacerbates TB infection after aerosol challenge in mice – implications for host-directed therapy** Rasmus Mortensen, Statens Serum Institute (Denmark)
PD-02	**Deciphering the role of VapBC TA modules in virulence and pathogenesis of Mycobacterium tuberculosis** Sakshi Agarwal, Translational Health Science and Technology Institute (India)
PD-03	**Mycobacterium tuberculosis hbhA and mtp deletion elicits unique canonical pathways during early infection in THP-1 differentiated macrophages** Suventha Moodley, University of KwaZula-Natal (South Africa)
PD-04	**Targeting ClpB abrogates stress tolerance in Mycobacterium tuberculosis and hence its growth and infectivity** Prajna Tripathi, National Institute of Immunology (India)
PD-05	**Circulating HLA-DR+IFNγhiIL-17hiCD4+T effectors resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis** Asma Ahmed, Indian Institute of Science (India)
PD-06	**PPM, a novel Mycobacterium tuberculosis (Mtb) antigen: a candidate for vaccine development to prevent progression to tuberculosis** Chaouki Benabdessalem, Institut Pasteur de Tunis (Tunisia)
PD-07	**Evaluation of the immunogenicity of a promising vaccine regime to identify immune correlates of protection** Nawamin Pinpathomrat, University of Oxford (UK)
PD-08	**Demonstration of a correlation between the in vitro direct mycobacterial growth inhibition assay (MGIA) and protection from in vivo mycobacterial challenge** Rachel Tanner, University of Oxford (UK)
PD-09	**Altered systemic levels of neutrophil and mast cell granular proteins in tuberculosis-diabetes co-morbidity and changes following treatment** Kadar Abbas Moideen, National Institute of Health-NIRT-International Center for Excellence in Research (India)
	POSTER DISCUSSION 2: DIAGNOSTICS AND EPIDEMIOLOGY
Sheesh Mahal	Facilitators: Johan Vekemans, Initiative for Vaccine Research, World Health Organization (Switzerland) | Jaya Tyagi, Department of Biotechnology, All India Institute of Medical Sciences (India)
PD-22	**BCG vaccine as proof-of-concept** Marcel Behr, McGill University (Canada)
PD-23	**Effect of anti-tuberculosis treatment on the systemic levels of matrix metalloproteinases and tissue inhibitors of MMP in tuberculosis – diabetes co-morbidity** Nathella Pavan Kumar, NIH-ICER-NIRT (India)
PD-24	**The ESAT-6 free IGRA, a companion diagnostic for ESAT-6 based TB vaccines** Morten Ruhwald, Statens Serum Institut (Denmark)
PD-25	**Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosis** Srabanti Rakshit, Indian Institute of Science (India)

PD-26	**Proliferative T cell (CD3+Ki67+) response to PPD and M. tuberculosis cell membrane complements the tuberculin skin test for detection of latent TB infection in healthy North Indian hospital contacts** Sudhir Sinha, Sanjay Gandhi Post-Graduate Institute of Medical Sciences (India)
PD-27	**CD14+ CD16+ cells as immunological marker for protection in household contacts with latent tuberculosis infection** Venkata Sanjeev Kumar Neela, Bhagwan Mahavir Medical Research Centre (India)
PD-28	**Optimization and interpretation of serial QuantiFERON testing to measure acquisition of M. tuberculosis infection** Elisa Nemes, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
PD-29	**Updating the recommended age of BCG vaccination? Modelling the potential impact on global paediatric TB mortality** Partho Roy, London School of Hygiene and Tropical Medicine (UK) *Presented by Rebecca Harris, London School of Hygiene and Tropical Medicine (UK)*
PD-30	**Do we have identified target groups and a population based strategy for vaccination against tuberculosis to cut down transmission?** U.D. Gupta, National JALMA Institute for Leprosy and Other Mycobacterial Diseases (India)
PD-31	**TB Infection among household contacts: Preventive therapy for all?** Chandra Kumar Dolla, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India)
PD-32	**Infection free "resistors" among household contacts of culture-confirmed adult pulmonary TB cases** Vidya Mave, Byramjee Jeejeebhoy Government Medical College - Johns Hopkins University Clinical Research Site (India)
PD-33	**Incidence of Mycobacterium tuberculosis infection among household contacts of adult pulmonary tuberculosis cases in India** Mandar Paradkar, Byramjee Jeejeebhoy Government Medical College Clinical Research Site (India)
Mumtaz Mahal	**POSTER VIEWING: NOVEL VACCINE CONCEPTS; CHEMISTRY, MANUFACTURING AND CONTROLS**
	NOVEL VACCINE CONCEPTS
PA-01	**The impact of previous BCG vaccination in enhancing the effectiveness of tuberculosis drugs to control mycobacterial growth ex-vivo** Satria Arief Prabowo, London School of Hygiene and Tropical Medicine (UK)
PA-02	**The role of DPP4 and antagonist CXCL10 in the pathogenesis of TB, an opportunity for vaccines and HDT?** Morten Ruhwald, Statens Serum Institut (Denmark)
PA-03	**Mycobacterium tuberculosis H37Rv cell wall isolated poly L-glutamines as novel Th1-biased adjuvant** Manish Gupta, Jawaharlal Nehru University (India)
PA-04	**De novo arginine biosynthesis pathway of Mycobacterium tuberculosis: A novel drug target and potential vaccine candidate** Sangeeta Tiwari, Albert Einstein College of Medicine (USA)
PA-05	**Epitope-based vaccine design for Mycobacterium tuberculosis strains through pan-genomic reverse vaccinology** Ravina Madhulitha Nalamolu, Sri Venkateswara Institute of Medical Sciences University (India)
PA-06	**Development of a recombinant BCG vaccine expressing a monomeric form of ESAT-6** Makram Essafi, Institut Pasteur de Tunis (Tunisia)
PA-07	**Insights into mycobacterial membrane vesicles: a potential subunit vaccine candidate** Praapti Jayaswal, Translational Health Science and Technology Institute (India)
PA-08	**Assessment of the protective effect, against tuberculosis, of a new vaccine composition** Rania Bouzeyen, Insitut Pasteur de Tunis (Tunisia)
PA-09	**Immunological activity of the fusion protein consisted of the major secretory protein of Mycobacterium tuberculosis** Hyun Shik Bae, Chungnam National University (South Korea)
PA-10	**Synthetic polysaccharide conjugate vaccines expressing Mycobacterium tuberculosis antigens induce high-titer antibody responses in mice, guinea pigs, and rabbits** Dominick Laddy, Aeras (USA)
PA-11	**Rv2882c-Rv20xxc, a novel immunostimulatory antigen of Mycobacterium tuberculosis, activates bone-marrow derived dendritic cell** Ki-Won Shin, College of Medicine, Chungnam National University (South Korea)

PA-12	**Mycobacterium tuberculosis protein Rv2299c fused-ESAT-6 subunit vaccine confers improved protection against the hypervirulent strain HN878 in mice** Seunga Choi, College of Medicine, Chungnam National University (South Korea)
PA-13	**Evaluation of attenuated strains as auxotrophic vaccines against Mycobacterium tuberculosis** Tannu Priya Gosain, Translational Health Science and Technology Institute (India)
	CHEMISTRY, MANUFACTURING AND CONTROLS
PA-14	**Miniaturized fluorescence adapter for fluorescence sputum smear microscopy using bright-field microscope** Pooja Singh, IIT Delhi (India)
PA-15	**Development of an innovative, rapid, affordable and automated system for selective enrichment, isolation and detection of MTB in sputum sample** Saumya Singh, IIT Delhi (India)
PA-16	**Comparison of pellicle and liquid grown BCG reference strains in standard BCG batch release assays and protection studies** Megan Fitzpatrick, Aeras (USA)

Wednesday 21 February 2018

16:30 – 18:00	**POSTER DISCUSSION 3: PRECLINICAL RESEARCH**
Roshanara	Facilitators: Danilo Casimiro, former Aeras (USA) | Sarala Balachandran, Council of Scientific and Industrial Research (India)
PD-10	**Early and local immune mechanisms of TB disease progression and control upon ultra-low dose infection in rhesus versus cynomolgus macaques** Karin Djikman, Biomedical Primate Research Centre (Netherlands)
PD-11	**Experimental evaluation of a novel microneedle device for BCG vaccination** Jungho Kim, International Tuberculosis Research Center (South Korea) *Presented by Jake Whang, International Tuberculosis Research Center (South Korea)*
PD-12	**Role of BCG encapsulated alginate particles in activation of bone marrow derived dendritic cells for providing better immune response against TB** Ashwani Kesarwani, National Institute of Immunology; Jamia Handard (India)
PD-13	**bioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs** Ritika Kar Bahal, University of Delhi South Campus (India)
PD-14	**Animal dose response curve predicts lower optimal tuberculosis vaccine dose in humans: The use of vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making** Sophie Rhodes, London School of Hygiene and Tropical Medicine (UK) *Presented by Richard White, London School of Hygiene and Tropical Medicine (UK)*
PD-15	**T cell immunity in the lung and protection following aerosol, intravenous, or intradermal administration of BCG in nonhuman primates** Patricia Darrah, National Institute of Immunology and Infectious Diseases, National Institutes of Health (USA)
PD-16	**A recombinant BCG-LTAK63 strain induces increased innate and long-term immunity correlating with enhanced protection against tuberculosis** Luciana Leite, Instituto Butantan (Brazil)
PD-17	**Recombinant BCG-LTAK63 strain induces lower immunopathological effects and superior protection against tuberculosis in BALB/c and C57BL/6 mice** Carina Santos, Instituto Butantan (Brazil)
PD-18	**Intransal vaccination with Mycobacterium indicus pranii leads to infiltration of protective memory T-cells in lung airway lumen** Ananya Gupta, National Institute of Immunology (India)
PD-19	**Boosting with recombinant MVA expressing α-crystallin antigen of M. tuberculosis augments the protection imparted by BCG against tuberculosis in guinea pigs** Prachi Nangpal, University of Delhi South Campus (India)
PD-20	**A single dose nanoparticulate vaccine approach against tuberculosis** Manish Gupta, Jawaharlal Nehru University (India)

PD-21	**Passive vaccination with human IgA protects against MDR-TB infection in mice** Andy Tran, St. George's University of London (UK)
	POSTER DISCUSSION 4: CLINICAL RESEARCH AND COMMUNITY ENGAGEMENT
Sheesh Mahal	Facilitators: Souleymane Mboup, Institut de Recherche en Santé, de Surveillance Epidemiologique et de Formations (Senegal) | Lorraine Misquith, Lawyers Collective and Global Coalition of TB Activists (India)
PD-34	**Immunogenicity of AERAS-404 or BCG revaccination in a prevention of established M. tuberculosis infection efficacy trial** Virginie Rozot, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
PD-35	**Phase 1 clinical trial to evaluate the safety and immunogenicity of an adenovirus-based tuberculosis vaccine (Ad5Ag85A) administered by aerosol to healthy volunteers** Fiona Mary Smaill, McMaster University (Canada)
PD-36	**Dose definition of the novel TB vaccine ID93 + GLA-SE for TB endemic countries** Adam Penn-Nicholson, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
PD-37	**The Toll-like receptor 4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine** Tracey Ann Day, Infectious Disease Research Institute (USA)
PD-38	**Safety and immunogenicity of H56:IC31 in HIV negative adults with and without latent tuberculosis (TB) infection** Angelique Kani Kani Luabeya, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
PD-39	**Impact of implementing an effective community engagement strategy on retention rates in a Phase 2b TB disease prevention vaccine trial in South Africa, Zambia, and Kenya** Anja van der Westhuizen, Aeras Africa (South Africa)
PD-40	**Building a portfolio of community engagement projects to enhance TB** Michele Tameris, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
PD-41	**Drama as a community engagement tool to raise TB awareness** Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
PD-42	**Leveraging libraries to raise awareness about TB on World TB Day** Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
PD-43	**Using eCompliance for tracking patients and ensuring accuracy of data in vaccine trials** Shelly Batra, Operation ASHA (India)
Mumtaz Mahal	**POSTER VIEWING: BASIC SCIENCE RESEARCH, BIOMARKERS AND CORRELATES, EPIDEMIOLOGY**
	BASIC SCIENCE RESEARCH; BIOMARKERS OF CORRELATES OF IMMUNITY AND PROTECTION
PA-17	**Functional, antigen-specific stem cell-like memory (Tscm) CD4+ T cells are induced by human Mycobacterium tuberculosis infection** Cheleka Anne-Marie Mpande, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
PA-18	**Activation of L-type voltage gated calcium channel in macrophages suppresses protective responses during Mycobacterium tuberculosis infection** Deepika Sharma, University of Delhi (India)
PA-19	**Role of phosphorylation on secretion in Mycobacterium tuberculosis and its impact on its survival** Basanti Malakar, National Institute of Immunology (India)
PA-20	**Challenges in detecting TB drug resistance in a field setting in Southwestern Uganda** Patrick Orikiriza, Mbarara University of Science and Technology (Uganda)
PA-21	**Calcimycin induced autophagy decreases mycobacterial growth in THP-1 cells through P2RX7 dependent pathway mediated by intracellular calcium** Shradha Mawatwal, National Institute of Technology, Rourkela (India)
PA-22	**Phenotypic adaptation to drug treatment in Mycobacterium tuberculosis is mediated by DNA gyrase** Eira Choudhary, Translational Health and Science Technology Institute (India)

PA-23 **Assessment of anti-mycobacterial activity of some selected Congolese medicinal plants**
Gedeon Ngiala Bongo, University of Kinshasa (Democratic Republic of Congo)

PA-24 **Various aspects of GTPases towards its essentiality in survival and pathogenesis of Mycobacterium tuberculosis H37Rv**
Shivangi, CSIR-Institute of Genomics and Integrative Biology (India)

PA-25 **Cytokines, matrix metalloproteinases, angiogenic factors and acute phase proteins as biomarkers in tuberculous lymphadenitis**
Gokul Raj Kathamuthu, National Institute for Research in Tuberculosis (NIRT)-NIH-ICER (India)

PA-26 **Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis**
Hyejon Lee, Yonsei University College of Medicine (South Korea)
Presented by Bora Sim, Yonsei University College of Medicine (South Korea)

EPIDEMIOLOGY

PA-27 **Sputum sample collection for diagnosis of pediatric pulmonary tuberculosis, does method and site of sample collection matter?**
Willy Ssengooba, Makerere University (Uganda)

PA-28 **Tuberculosis massive active case discovery in East Jakarta 2016-2017: the role of Ketuk Pintu Layani Dengan Hati (KPLDH) and Juru Pemantau Batuk (Jumantuk) cadre programs**
Ngabila Salama, East Jakarta Health Office (Indonesia)

PA-29 **Clinical profile of tuberculous meningitis in a tertiary care center in India**
Anita Basavaraj, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India)